Lexaria Bioscience Corp. (NASDAQ: LEXX) Publishes Eighth Peer-Reviewed Article in International Journal of Molecular Science
- The article covers the concentration of cannabidiol in hypertensive women and men using the company’s patented DehydraTECH(TM)-processed CBD
- The global cardiovascular drugs market is expected to grow from $146.51 billion in 2021, reaching $173.48 billion in 2026, growing at a CAGR of 3.1%
- The article supports Lexaria’s efforts as it pursues IND status from the FDA for DehydraTECH-CBD as a potential treatment for hypertension
- Company is planning to begin preparations for a clinical trial that could start as early as the fourth quarter
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that its groundbreaking research utilizing its patented DehydraTECH(TM)-processed cannabidiol (DehydraTECH-CBD) has been published in eight peer-reviewed articles across six different publications. Lexaria’s research into DehydraTECH-CBD is being considered for indications including hypertension, diabetes, epilepsy, and more. Hypertension, heart disease, and diabetes are broad fields of interest for the company, with DehydraTECH-CBD generating positive pilot-study data.
“We’re proud of the impressive amount of research that our Company has been able to develop through its HYPER-H21 series of clinical studies that has now been assessed by a variety of our respected peers,” said John Docherty, President of Lexaria (https://nnw.fm/qtDwH ). “Lexaria is establishing itself as one of the world’s leaders in the investigation of cannabidiol for the purposes of controlling human blood pressure, and we are now focused on launching an FDA-registered IND program to formally investigate DehydraTECH-CBD for hypertension this year.”
The global cardiovascular drugs market is expected to grow from $146.51 billion in 2021, reaching $173.48 billion in 2026, growing at a CAGR of 3.1%. The market’s growth is supported by the increase in sedentary jobs, busy lifestyles, and changing consumer preferences – factors affecting the disease profile in world populations. North America contributed as the largest cardiovascular drug region in 2021 (https://nnw.fm/Kr4Pr ).
The most recent publication in June 2023 in the peer-reviewed International Journal of Molecular Sciences is “Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study” (https://nnw.fm/d6NY0 ). The addition of this research article builds on the growing body of peer-reviewed literature developed by Lexaria’s leading research team into the effects of DehydraTECH-CBD and human health.
The findings and conclusions from the most recently published article revolve around the concentrations of CBD in a subject’s plasma and the bioavailability of the drug, examining the potential therapeutic benefits of CBD in the triple-blind study. Of the 62 hypertensive volunteers, concentrations of CBD were found to be higher in women and correlated with the proportion of adipose tissue. Lexaria found that the difference between the sexes was attributed to higher levels of fat tissue in women compared to men, and the men’s higher metabolism contributed to lower levels of CBD during the study.
Lexaria’s patented DehydraTECH technology improves how active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble molecules. DehydraTECH is covered by 34 granted patents and many pending patents.
The benefits of using DehydraTECH technology include:
Improves the speed of onset, with effects felt in minutes
Increased bioavailability by more effectively delivering the drug into the bloodstream
Increased brain absorption, with testing suggesting up to 17x improvement
Reduction in drug administration costs through a higher ratio of drug delivery
Lexaria’s next steps for its hypertension program include IND submission and additional preparations for its clinical trial. If the FDA clears the IND, Lexaria could begin its Phase Ib study as early as the fourth quarter of this year.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- The article covers the concentration of cannabidiol in hypertensive women and men using the company’s patented DehydraTECH(TM)-processed CBD
- The global cardiovascular drugs market is expected to grow from $146.51 billion in 2021, reaching $173.48 billion in 2026, growing at a CAGR of 3.1%
- The article supports Lexaria’s efforts as it pursues IND status from the FDA for DehydraTECH-CBD as a potential treatment for hypertension
- Company is planning to begin preparations for a clinical trial that could start as early as the fourth quarter
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that its groundbreaking research utilizing its patented DehydraTECH(TM)-processed cannabidiol (DehydraTECH-CBD) has been published in eight peer-reviewed articles across six different publications. Lexaria’s research into DehydraTECH-CBD is being considered for indications including hypertension, diabetes, epilepsy, and more. Hypertension, heart disease, and diabetes are broad fields of interest for the company, with DehydraTECH-CBD generating positive pilot-study data.
“We’re proud of the impressive amount of research that our Company has been able to develop through its HYPER-H21 series of clinical studies that has now been assessed by a variety of our respected peers,” said John Docherty, President of Lexaria (https://nnw.fm/qtDwH ). “Lexaria is establishing itself as one of the world’s leaders in the investigation of cannabidiol for the purposes of controlling human blood pressure, and we are now focused on launching an FDA-registered IND program to formally investigate DehydraTECH-CBD for hypertension this year.”
The global cardiovascular drugs market is expected to grow from $146.51 billion in 2021, reaching $173.48 billion in 2026, growing at a CAGR of 3.1%. The market’s growth is supported by the increase in sedentary jobs, busy lifestyles, and changing consumer preferences – factors affecting the disease profile in world populations. North America contributed as the largest cardiovascular drug region in 2021 (https://nnw.fm/Kr4Pr ).
The most recent publication in June 2023 in the peer-reviewed International Journal of Molecular Sciences is “Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study” (https://nnw.fm/d6NY0 ). The addition of this research article builds on the growing body of peer-reviewed literature developed by Lexaria’s leading research team into the effects of DehydraTECH-CBD and human health.
The findings and conclusions from the most recently published article revolve around the concentrations of CBD in a subject’s plasma and the bioavailability of the drug, examining the potential therapeutic benefits of CBD in the triple-blind study. Of the 62 hypertensive volunteers, concentrations of CBD were found to be higher in women and correlated with the proportion of adipose tissue. Lexaria found that the difference between the sexes was attributed to higher levels of fat tissue in women compared to men, and the men’s higher metabolism contributed to lower levels of CBD during the study.
Lexaria’s patented DehydraTECH technology improves how active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble molecules. DehydraTECH is covered by 34 granted patents and many pending patents.
The benefits of using DehydraTECH technology include:
Improves the speed of onset, with effects felt in minutes
Increased bioavailability by more effectively delivering the drug into the bloodstream
Increased brain absorption, with testing suggesting up to 17x improvement
Reduction in drug administration costs through a higher ratio of drug delivery
Lexaria’s next steps for its hypertension program include IND submission and additional preparations for its clinical trial. If the FDA clears the IND, Lexaria could begin its Phase Ib study as early as the fourth quarter of this year.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
